Pharming (PHAR) Non-Current Assets (2019 - 2026)

Pharming (PHAR) has 8 years of Non-Current Assets data on file, last reported at $187.3 million in Q2 2026.

• Quarterly Non-Current Assets fell 6.58% year-over-year to $187.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $187.3 million (down 6.58% YoY) and the FY2025 annual result came in at $200.5 million, up 64.96% from the prior year.
• Non-Current Assets retreated to $187.3 million in Q2 2026, from $193.9 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $200.5 million in Q4 2025 to a low of $130275.0 in Q3 2022.
• A 5-year average of $152.7 million and a median of $147.4 million in 2022 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets slumped 99.92% — and 2023, when it surged 110995.76%.
• Tracing PHAR's Non-Current Assets over 5 years: stood at $148.3 million in 2022, then dropped by 1.2% to $146.5 million in 2023, then declined by 17.04% to $121.5 million in 2024, then soared by 64.96% to $200.5 million in 2025, then dropped by 6.58% to $187.3 million in 2026.
• The last three Non-Current Assets figures came in at $187.3 million (Q2 2026), $193.9 million (Q1 2026), and $200.5 million (Q4 2025), per Business Quant data.